<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: -Previously, we showed a mouse model (ACE8/8) of cardiac renin-angiotensin system (<z:mp ids='MP_0011356'>RAS</z:mp>) activation has a high rate of spontaneous <z:hpo ids='HP_0004756'>ventricular tachycardia</z:hpo> (VT) and <z:hpo ids='HP_0001645'>sudden cardiac death</z:hpo> (SCD) secondary to a reduction in connexin43 (Cx43) level </plain></SENT>
<SENT sid="1" pm="."><plain><z:chebi fb="0" ids="2719,48432">Angiotensin-II</z:chebi> activation increases reactive oxygen species (ROS) production, and ACE8/8 mice show increased cardiac ROS </plain></SENT>
<SENT sid="2" pm="."><plain>We sought to determine the source of ROS and if ROS played a role in the arrhythmogenesis </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS AND RESULTS: -<z:mp ids='MP_0002169'>Wild-type</z:mp> and ACE8/8 mice with and without two weeks of treatment with L-NIO (nitric <z:chebi fb="177" ids="25741,29356">oxide</z:chebi> synthase inhibitor), <z:chebi fb="0" ids="16095">sepiapterin</z:chebi> (precursor of tetrahydrobiopterin), MitoTEMPO (mitochondria-targeted <z:chebi fb="11" ids="22586">antioxidant</z:chebi>), TEMPOL (a general <z:chebi fb="11" ids="22586">antioxidant</z:chebi>), <z:chebi fb="0" ids="2781">apocynin</z:chebi> (<z:chebi fb="0" ids="50423">NADPH oxidase inhibitor</z:chebi>), <z:chebi fb="0" ids="40279">allopurinol</z:chebi> (<z:chebi fb="0" ids="35634">xanthine oxidase inhibitor</z:chebi>), and ACE8/8 crossed with P67 dominant negative mice to inhibit the <z:chebi fb="1" ids="16474">NADPH</z:chebi> oxidase were studied </plain></SENT>
<SENT sid="4" pm="."><plain>Western blotting, detection of <z:hpo ids='HP_0001427'>mitochondrial</z:hpo> ROS by MitoSOX Red, electron microscopy, immunohistochemistry, <z:chebi fb="2" ids="51121">fluorescent dye</z:chebi> diffusion technique for functional assessment of Cx43, telemetry monitoring, and in-vivo electrophysiology studies were performed </plain></SENT>
<SENT sid="5" pm="."><plain>Treatment with MitoTEMPO reduced SCD in ACE8/8 mice (from 74% to 18%, P&lt;0.005), decreased spontaneous <z:mp ids='MP_0009732'>ventricular premature beats</z:mp>, decreased VT inducibility (from 90% to 17%, P&lt;0.05), diminished elevated <z:hpo ids='HP_0001427'>mitochondrial</z:hpo> ROS to the control level, prevented structural damage to mitochondria, resulted in 2.6 fold increase in Cx43 level at the gap junctions, and corrected gap junction conduction </plain></SENT>
<SENT sid="6" pm="."><plain>None of the other <z:chebi fb="11" ids="22586">antioxidant</z:chebi> therapies prevented VT and SCD in ACE8/8 mice </plain></SENT>
<SENT sid="7" pm="."><plain>CONCLUSIONS: -<z:hpo ids='HP_0001427'>Mitochondrial</z:hpo> <z:mp ids='MP_0003674'>oxidative stress</z:mp> plays a central role in <z:chebi fb="0" ids="2719,48432">angiotensin II</z:chebi>-induced gap junction remodeling and <z:hpo ids='HP_0011675'>arrhythmia</z:hpo> </plain></SENT>
<SENT sid="8" pm="."><plain>Mitochondria-targeted <z:chebi fb="11" ids="22586">antioxidants</z:chebi> may be effective antiarrhythmic drugs in cases of <z:mp ids='MP_0011356'>RAS</z:mp> activation </plain></SENT>
</text></document>